Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | TEK | Q02763 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 4/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846831 | 0.94 | KDR (0.38) | KDRTEKLCKPTPN11ABL1 | |
| SCHEMBL6846825 | 0.85 | ABL1 (0.42) | KDRTEKLCKPTPN11ABL1 | |
| SCHEMBL6846828 | 0.82 | LCK (0.44) | KDRTEKLCKABL1TSHR | |
| SCHEMBL6846781 | 0.78 | KDR (0.39) | KDRTEKLCKABL1MAPT | |
| SCHEMBL6846784 | 0.75 | TEK (0.39) | KDRTEKLCKABL1MAPT | |
| SCHEMBL7228824 | 0.73 | WNT3A (0.42) | PTPN11MEN1MAPTTSHRKMT2A | |
| SCHEMBL6844794 | 0.71 | MAP3K20 (0.39) | MEN1KMT2AATMKITFLT3 | |
| SCHEMBL6846894 | 0.69 | ABL1 (0.43) | KDRTEKLCKABL1ADK | |
| SCHEMBL18163278 | 0.69 | MAPT (0.47) | MEN1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL6846837 | 0.69 | MAP3K20 (0.36) | KDRMEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KDR 50/4885TEK 387/4885LCK 90/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KDR 50/4885TEK 387/4885LCK 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.